Trials / Terminated
TerminatedNCT03656692
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acthar Gel | Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL) |
Timeline
- Start date
- 2018-10-05
- Primary completion
- 2020-07-14
- Completion
- 2020-07-14
- First posted
- 2018-09-04
- Last updated
- 2021-08-03
- Results posted
- 2021-08-03
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03656692. Inclusion in this directory is not an endorsement.